Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

In the wake of US funding cuts for global aid, numerous donor-funded health facilities in South Africa have shut down and ...

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Older women with HIV face complex, intersectional challenges that warrant more support, according to a scoping review with ...

The FDA has accepted under Priority Review the NDA for lenacapavir for the prevention of HIV as pre-exposure prophylaxis.

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people living with HIV and outlines future research priorities.

Prevalence varies by region and is impacted by social stigma, access to preventive medicine and a lack of HIV/AIDS education, ...